NCT05303038Unknown2 期
A Phase II Clinical Study of Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic Triple Negative Breast Cancer Patients Failed by Multiline Therapy
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- ORR
研究概览
简要总结
This is a Phase II, open-label study evaluating the efficacy and safety of Cryoablation combined with Tirelizumab and Bevacizumab in liver metastatic triple-negative breast cancer patients failed by multiline therapy.
详细描述
This is a prospective, single-arm, single-center phase II clinical trial in liver metastatic triple-negative breast cancer patients failed by multiline therapy.
All subjects will receive cryoablation combined with tirelizumab + bevacizumab:
- Cryoablation of liver metastases: Cryoablation of 1-2 typical metastatic lesions will be performed on D1 under general anesthesia and ultrasound guidance for two cycles. If the patient has no measurable lesions outside the liver, the measurable lesions should be retained after partial ablation of the liver lesions.
- PD-1 antibody + anti vascular therapy: patients will receive 200mg Tirelizumab ( IV Q3W) + Bevacizumab 7.5mg/kg ( IV Q3W) at D14 after cryoablation until there is disease progression, intolerable toxic reaction, subject withdraws informed consent or the study ends (whichever comes first).
- Puncture biopsy of liver metastases will completed 1-3 days before cryoablation, 1-3 days before the first treatment with tirelizumab + bevacizumab, 2 cycles after treatment with tirelizumab + bevacizumab and after disease progression, and blood samples (about 10ml) were collected for mutation load detection and immune function evaluation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically or Imageologically confirmed liver metastatic tnbc patients;
- •Histologically confirmed diagnosis of TNBC characterized by estrogen receptor negative (ER-), progesterone receptor negative (PR-) and human epidermal growth factor-2 receptor negative (HER2-);
- •≥ 2 prior lines systemic therapy;
- •Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1);
- •The patients show no signs of bile duct obstruction, and the bilirubin is below the upper limit of 1.5x normal value (ULN);
- •Age ≥ 18 years on the day of signing the ICF (or the legal age of consent in the jurisdiction in which the study is taking place);
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- •The functions of the patient's organs and blood system meet the requirements;
- •Blood system function: absolute neutrophil count (ANC) ≥ 1.5 x 109 / L, platelet count ≥ 100 x 109 / L
- •Renal function: estimated glomerular filtration rate or creatinine clearance > 50 ml / min / 1.73 M2
- •Liver function: total bilirubin ≤ 1.5 x ULN, AST and alt ≤ 5 x ULN
- •Estimated survival time ≥12 weeks.
排除标准
- •The patient is currently receiving or has received irradiation or local treatment for the target lesion in the past 3 weeks.
- •The patient had previously received cryoablation.
- •The patient received major surgery within 14 days before enrolling in the study.
- •Palliative radiotherapy must be completed at least 2 weeks before enrolling in the study, and there is no plan for additional radiotherapy for the same lesion; ·Patients whose AE caused by radiotherapy did not recover to ≤ CTCAE 1 degree
- •The patient had metastatic brain lesions, including asymptomatic and well controlled lesions.
- •Complicated with infection and requiring intravenous antibiotic treatment.
- •The patient has any clinically significant disease or history that the investigator believes may endanger the safety of the patient or the reliability of the study results.
- •The patient has a history of any other malignancy unless the remission period exceeds 1 year. (do not exclude skin cancer, cervical cancer in situ, superficial bladder cancer, and breast cancer in radical treatment).
- •Female patients are pregnant or breastfeeding.
- •The patient received any trial drug within 14 days before receiving the first study drug.
- •The patient had undiminished or unstable severe toxicity (≥ CTCAE 4.0 grade 2) after previous use of another trial drug and / or previous cancer treatment, except anemia, weakness and hair loss.
- •Patients are allergic to the test drug or any of its excipients.
- •Patients are known to be HIV positive, have HCB, or have HBV infection and HBV DNA exceeds 2000 IU / ml.
- •The patient has a known history of drug addiction in the past 1 year, because this situation may lead to a high risk of non-compliance of the trial drug.
- •The patient has known active or suspected autoimmune disease. Subjects who are in a stable state and do not need systemic immunosuppressive therapy are allowed to be enrolled.
- •Subjects requiring systemic treatment with corticosteroids (> 10mg / day prednisone efficacy dose) or other immunosuppressants within 14 days before the administration of the study drug were allowed to inhale or locally use steroids and adrenal hormone replacement with a dose > 10mg / day prednisone efficacy dose in the absence of active autoimmune diseases.
- •The patient had a baseline corrected QT interval QTc > 450 ms, or the patient had known QT prolongation syndrome, torsade de pointe ventricular tachycardia, symptomatic ventricular tachycardia, unstable heart syndrome within 3 months before the screening visit, > grade 2 New York Heart Association heart failure, > grade 2 Canadian Cardiovascular Association angina pectoris.
结局指标
主要结局
ORR
时间窗: Up to 12 months
The number of people with tumor responses according to RECIST (V1.1): the proportion of participants who achieves a best overall response of complete response (CR) or partial response (PR).
次要结局
- Disease Control Rate (DCR)(Up to 12 months)
- Frequencies of Biomarkers(Up to 12 months)
- Duration of Response (DOR)(Up to 12 months)
- One-year overall survival (OS) rate(Up to 12 months)
- Progression-free Survival (PFS)(Up to 12 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial ConjunctivitisAcute Bacterial ConjunctivitisNCT05816070IVIEW Therapeutics Inc.129
Unknown
2 期
G-CSF and Autologous Cord Blood Infusion in Cerebral PalsyCerebral PalsyNCT02866331Hanyang University Seoul Hospital88
撤回
2 期
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast CancerEstrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor NegativeRecurrent Breast CarcinomaTriple Negative Breast CancerMetastatic Breast CancerNCT03644589University of Washington
招募中
2 期
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and CarboplatinLung Cancer, Small CellNCT06698965Shanghai Chest Hospital52
已完成
2 期
Oral Isotretinoin for Photoaging: Results of a Randomized Controlled Phase II TrialEpidermal p53 ExpressionPhotoagingNCT00701740Federal University of São Paulo32